ArticleFrontiers in pharmacology2025
Pelubiprofen and Shinbaro: a therapeutic approach for osteoarthritis in a murine medial meniscus destabilization model.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Current osteoarthritis treatments can cause serious long-term side effects, and Shinbaro capsules have limited efficacy when used alone. We aimed to determine whether combining pelubiprofen and Shinbaro capsules could offer a more effective and safer treatment strategy for osteoarthritis. Methods: Primary chondrocytes treated with interleukin-1β were assessed under different conditions: Shinbaro capsules (200 μg/mL), pelubiprofen (25/50 µM), and Shinbaro capsules + pelubiprofen (200 μg/mL and 25 μM, respectively). Male C57BL/6 mice underwent medial meniscus destabilization surgery to induce osteoarthritis and were treated five times a week for 8 weeks with either a vehicle control (saline), Shinbaro capsules alone (100 mg/kg), pelubiprofen alone (1.5/4.5 mg/kg), or Shinbaro capsules + pelubiprofen (100 mg/kg and 1.5 mg/kg, respectively). Results: Shinbaro capsules + pelubiprofen significantly improved cell viability, inhibited nitric oxide production and lactate dehydrogenase activity, and reduced pro-inflammatory cytokine production more effectively than the individual treatments. Alcian blue staining showed a notable increase in expression intensity with Shinbaro capsules + pelubiprofen. In treated mice, combination treatment significantly reduced the hyaline cartilage/calcified cartilage ratio and synovitis scores, improved the Osteoarthritis Research Society International scores and subchondral bone plate thickness, and enhanced collagen regeneration. Key markers of healthy cartilage and growth plate activity were significantly upregulated, whereas markers involved in cartilage matrix degradation were markedly reduced with Shinbaro capsules + pelubiprofen. Behavioral tests showed significant improvements in pain sensitivity and joint function with combination treatment. Discussion: Shinbaro capsules + pelubiprofen effectively preserve chondrocytes, reduce inflammation, and alleviate osteoarthritis symptoms through synergistic mechanisms, making it a promising therapeutic strategy for osteoarthritis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.